Clinical Schizophrenia & Related Psychoses

Google Scholar citation report

Citations : 6601

Clinical Schizophrenia & Related Psychoses received 6601 citations as per Google Scholar report

Clinical Schizophrenia & Related Psychoses peer review process verified at publons

Indexed In

Citations Report

Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report

Articles published in Clinical Schizophrenia & Related Psychoses have been cited by esteemed scholars and scientists all around the world. Clinical Schizophrenia & Related Psychoses has got h-index 41, which means every article in Clinical Schizophrenia & Related Psychoses has got 41 average citations.

Following are the list of articles that have cited the articles published in Clinical Schizophrenia & Related Psychoses.

	2022	2021	2020	2019	2018
Year wise published articles	105	141	28	8	28
Year wise citations received	543	553	590	563	587

Journal total citations count	6601
Journal Impact Factor	6.49
Journal 5 years Impact Factor	12.17
Journal CiteScore	11.19
Journal h-index	41
Journal h-index since 2016	26

Raja, Michele. "Clozapine safety, 35 years later." Current drug safety 6, no. 3 (2011): 164-184. View at Publisher View at Google Scholar View at Indexing
Gitrome, Leslie. "Schizophrenia: what can we do about it?." Current Psychiatry 10, no. 6 (2011): 52-60. View at Publisher View at Google Scholar View at Indexing
Nooijen, Patty MM, Felix Carvalho, and Robert J. Flanagan. "Haematological toxicity of clozapine and some other drugs used in psychiatry." Human Psychopharmacology: Clinical and Experimental 26, no. 2 (2011): 112-119. View at Publisher View at Google Scholar View at Indexing
Nielsen, Jimmi, Christoph U. Correll, Peter Manu, and John M. Kane. "Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?." The Journal of clinical psychiatry 74, no. 6 (2013): 0-0. View at Publisher View at Google Scholar View at Indexing
Yüksel, Rabia Nazik, Di?dem Göverti, Aybeniz Civan Kahve, I??k Batuhan Çakmak, Çi?dem Yücel, and Erol Göka. "Galectin-1 and galectin-3 levels in patients with schizophrenia and their unaffected siblings." Psychiatric Quarterly 91, no. 3 (2020): 715-725. View at Publisher View at Google Scholar View at Indexing
Kantrowitz, Joshua T. "Targeting Serotonin 5-HT 2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches." CNS drugs (2020): 1-13. View at Publisher View at Google Scholar View at Indexing
Bodatsch, Mitja, Joachim Klosterkötter, and Jörg Daumann. "Contributions of experimental psychiatry to research on the psychosis prodrome." Frontiers in psychiatry 4 (2013): 170. View at Publisher View at Google Scholar View at Indexing
Roberts, Rosalinda C., Joy K. Roche, Shahza M. Somerville, and Robert R. Conley. "Ultrastructural distinctions between treatment responders and non-responders in schizophrenia: postmortem studies of the striatum." Mental Illness/Book 2 (2012): 261-286. View at Publisher View at Google Scholar View at Indexing
Kowalec, Kaarina, Yi Lu, Jie Song, Christina Dalman, Christina M. Hultman, Henrik Larsson, Paul Lichtenstein, and Patrick F. Sullivan. "The association between family history and genomic burden with schizophrenia mortality: a Swedish population-based register and genetic sample study." Translational psychiatry 11, no. 1 (2021): 1-9. View at Publisher View at Google Scholar View at Indexing
Walker, Ashley E., Jerrod D. Spring, and Michael J. Travis. "Addressing cognitive deficits in schizophrenia: Toward a neurobiologically informed approach." Biological psychiatry 81, no. 1 (2017): e1-e3. View at Publisher View at Google Scholar View at Indexing
Mosley, Jacqueline C. "The Economic Burden of Comorbid Serious Mental Illness and Chronic Non-communicable Disease in Working Age Adults in the United States." PhD diss., Tulane University, School of Public Health and Tropical Medicine, 2015. View at Publisher View at Google Scholar View at Indexing
Citrome, Leslie. "Treatment-refractory schizophrenia: what is it and what has been done about it?." Neuropsychiatry 1, no. 4 (2011): 325. View at Publisher View at Google Scholar View at Indexing
Stelzhammer, Viktoria, Bob Amess, Daniel Martins?de?Souza, Yishai Levin, Susan E. Ozanne, Malgorzata S. Martin?Gronert, Sebastian Urday, Sabine Bahn, and Paul C. Guest. "Analysis of the rat hypothalamus proteome by data?independent label?free LC?MS/MS." Proteomics 12, no. 22 (2012): 3386-3392. View at Publisher View at Google Scholar View at Indexing
Buckley, Peter F., and Brian J. Miller. "Rheumatoid Arthritis Drugs for Schizophrenia?." Psychiatric Annals 48, no. 5 (2018): 232-236. View at Publisher View at Google Scholar View at Indexing
Ethridge, Lauren, Stephan Moratti, Yuan Gao, Andreas Keil, and Brett A. Clementz. "Sustained versus transient brain responses in schizophrenia: the role of intrinsic neural activity." Schizophrenia research 133, no. 1-3 (2011): 106-111. View at Publisher View at Google Scholar View at Indexing
Krzystanek, Marek, and Artur Pa?asz. "NMDA receptor model of antipsychotic drug-induced hypofrontality." International journal of molecular sciences 20, no. 6 (2019): 1442. View at Publisher View at Google Scholar View at Indexing
Sapkota, Kiran, Mark W. Irvine, Guangyu Fang, Erica S. Burnell, Neil Bannister, Arturas Volianskis, Georgia R. Culley et al. "Mechanism and properties of positive allosteric modulation of N-methyl-D-aspartate receptors by 6-alkyl 2-naphthoic acid derivatives." Neuropharmacology 125 (2017): 64-79. View at Publisher View at Google Scholar View at Indexing
Muscatello, Maria Rosaria A., Antonio Bruno, Pasquale De Fazio, Cristina Segura-Garcia, Gianluca Pandolfo, and Rocco Zoccali. "Augmentation strategies in partial responder and/or treatment-resistant schizophrenia patients treated with clozapine." Expert opinion on pharmacotherapy 15, no. 16 (2014): 2329-2345. View at Publisher View at Google Scholar View at Indexing
Leppik, Liisa, Madis Parksepp, Sven Janno, Kati Koido, Liina Haring, Eero Vasar, and Mihkel Zilmer. "Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis." European archives of psychiatry and clinical neuroscience 270, no. 1 (2020): 59-70. View at Publisher View at Google Scholar View at Indexing
Kantrowitz, Joshua T., and Leslie Citrome. "Lurasidone for schizophrenia: what’s different?." Expert review of neurotherapeutics 12, no. 3 (2012): 265-273. View at Publisher View at Google Scholar View at Indexing
Prev 1 2 ... 27 28 29 30 31 32 33 34 35 36 37 ... 84 85 Next »

Google Scholar citation report

Citations : 6601

Clinical Schizophrenia & Related Psychoses peer review process verified at publons

Indexed In

PMC/PubMed Indexed Articles

Citations Report

Clinical Schizophrenia & Related Psychoses : Citations & Metrics Report

Raja, Michele. "Clozapine safety, 35 years later." Current drug safety 6, no. 3 (2011): 164-184.

Gitrome, Leslie. "Schizophrenia: what can we do about it?." Current Psychiatry 10, no. 6 (2011): 52-60.

Nooijen, Patty MM, Felix Carvalho, and Robert J. Flanagan. "Haematological toxicity of clozapine and some other drugs used in psychiatry." Human Psychopharmacology: Clinical and Experimental 26, no. 2 (2011): 112-119.

Nielsen, Jimmi, Christoph U. Correll, Peter Manu, and John M. Kane. "Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?." The Journal of clinical psychiatry 74, no. 6 (2013): 0-0.

Yüksel, Rabia Nazik, Di?dem Göverti, Aybeniz Civan Kahve, I??k Batuhan Çakmak, Çi?dem Yücel, and Erol Göka. "Galectin-1 and galectin-3 levels in patients with schizophrenia and their unaffected siblings." Psychiatric Quarterly 91, no. 3 (2020): 715-725.

Kantrowitz, Joshua T. "Targeting Serotonin 5-HT 2A Receptors to Better Treat Schizophrenia: Rationale and Current Approaches." CNS drugs (2020): 1-13.

Bodatsch, Mitja, Joachim Klosterkötter, and Jörg Daumann. "Contributions of experimental psychiatry to research on the psychosis prodrome." Frontiers in psychiatry 4 (2013): 170.

Roberts, Rosalinda C., Joy K. Roche, Shahza M. Somerville, and Robert R. Conley. "Ultrastructural distinctions between treatment responders and non-responders in schizophrenia: postmortem studies of the striatum." Mental Illness/Book 2 (2012): 261-286.

Walker, Ashley E., Jerrod D. Spring, and Michael J. Travis. "Addressing cognitive deficits in schizophrenia: Toward a neurobiologically informed approach." Biological psychiatry 81, no. 1 (2017): e1-e3.

Mosley, Jacqueline C. "The Economic Burden of Comorbid Serious Mental Illness and Chronic Non-communicable Disease in Working Age Adults in the United States." PhD diss., Tulane University, School of Public Health and Tropical Medicine, 2015.

Citrome, Leslie. "Treatment-refractory schizophrenia: what is it and what has been done about it?." Neuropsychiatry 1, no. 4 (2011): 325.

Stelzhammer, Viktoria, Bob Amess, Daniel Martins?de?Souza, Yishai Levin, Susan E. Ozanne, Malgorzata S. Martin?Gronert, Sebastian Urday, Sabine Bahn, and Paul C. Guest. "Analysis of the rat hypothalamus proteome by data?independent label?free LC?MS/MS." Proteomics 12, no. 22 (2012): 3386-3392.

Buckley, Peter F., and Brian J. Miller. "Rheumatoid Arthritis Drugs for Schizophrenia?." Psychiatric Annals 48, no. 5 (2018): 232-236.

Ethridge, Lauren, Stephan Moratti, Yuan Gao, Andreas Keil, and Brett A. Clementz. "Sustained versus transient brain responses in schizophrenia: the role of intrinsic neural activity." Schizophrenia research 133, no. 1-3 (2011): 106-111.

Krzystanek, Marek, and Artur Pa?asz. "NMDA receptor model of antipsychotic drug-induced hypofrontality." International journal of molecular sciences 20, no. 6 (2019): 1442.

Sapkota, Kiran, Mark W. Irvine, Guangyu Fang, Erica S. Burnell, Neil Bannister, Arturas Volianskis, Georgia R. Culley et al. "Mechanism and properties of positive allosteric modulation of N-methyl-D-aspartate receptors by 6-alkyl 2-naphthoic acid derivatives." Neuropharmacology 125 (2017): 64-79.

Leppik, Liisa, Madis Parksepp, Sven Janno, Kati Koido, Liina Haring, Eero Vasar, and Mihkel Zilmer. "Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis." European archives of psychiatry and clinical neuroscience 270, no. 1 (2020): 59-70.

Kantrowitz, Joshua T., and Leslie Citrome. "Lurasidone for schizophrenia: what’s different?." Expert review of neurotherapeutics 12, no. 3 (2012): 265-273.